Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × belantamab mafodotin × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 10 Neoplasms, Plasma Cell 2 Immunoglobulin Light-chain Amyloidosis 2 Amyloidosis 2 Recurrence 1 Plasmablastic Lymphoma 1

Interventions

Cyclophosphamide 26 fludarabine 21 pembrolizumab 17 Dexamethasone 16 Rituximab 14 venetoclax 12 Gemcitabine 9 Vincristine 8 Temozolomide 8 Lenalidomide 8 Etoposide 8 glofitamab 7 Cytarabine 7 pomalidomide 6 obinutuzumab 6 Prednisone 6 Nivolumab 6 Doxorubicin 6 Calcium Dobesilate 6 zanubrutinib 5 fludarabine phosphate 5 carfilzomib 5 Carboplatin 5 ruxolitinib 4 Radiotherapy 4 Paclitaxel 4 Capecitabine 4 Bortezomib 4 Bevacizumab 4 Azacitidine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05714839 2026-01-23

DREAMM-20

GlaxoSmithKline

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡